Zobrazeno 1 - 10
of 344
pro vyhledávání: '"Vincent J, Gnanapragasam"'
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background The majority of men referred with a raised PSA for suspected prostate cancer will receive unnecessary tertiary investigations including MRI and biopsy. Here, we compared different types of biomarkers to refine tertiary referrals a
Externí odkaz:
https://doaj.org/article/940d450a9266478ea32be48d83014378
Autor:
Nikita Sushentsev, Gregory Hamm, Lucy Flint, Daniel Birtles, Aleksandr Zakirov, Jack Richings, Stephanie Ling, Jennifer Y. Tan, Mary A. McLean, Vinay Ayyappan, Ines Horvat Menih, Cara Brodie, Jodi L. Miller, Ian G. Mills, Vincent J. Gnanapragasam, Anne Y. Warren, Simon T. Barry, Richard J. A. Goodwin, Tristan Barrett, Ferdia A. Gallagher
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)
Abstract Hyperpolarised magnetic resonance imaging (HP-13C-MRI) has shown promise as a clinical tool for detecting and characterising prostate cancer. Here we use a range of spatially resolved histological techniques to identify the biological mechan
Externí odkaz:
https://doaj.org/article/5d269719830146bfb19310f180c8fbe9
Autor:
Harry Gabb, Vincent J. Gnanapragasam
Publikováno v:
BJUI Compass, Vol 5, Iss 7, Pp 662-664 (2024)
Externí odkaz:
https://doaj.org/article/0cbedc87858a4a4cb07f2b71f7f6e86d
Autor:
Ermira Lleshi, Toby Milne-Clark, Henson Lee Yu, Henno W. Martin, Robert Hanson, Radoslaw Lach, Sabrina H. Rossi, Anja Lisa Riediger, Magdalena Görtz, Holger Sültmann, Andrew Flewitt, Andy G. Lynch, Vincent J. Gnanapragasam, Charlie E. Massie, Harveer S. Dev
Publikováno v:
iScience, Vol 27, Iss 7, Pp 110330- (2024)
Summary: Prostate cancer screening using prostate-specific antigen (PSA) has been shown to reduce mortality but with substantial overdiagnosis, leading to unnecessary biopsies. The identification of a highly specific biomarker using liquid biopsies,
Externí odkaz:
https://doaj.org/article/e8df49dd662441c084902b69e9243587
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 15-22 (2023)
Background: Active surveillance (AS) is a major management option for men with early prostate cancer. Current guidelines however advocate identical AS follow-up for all without considering different disease trajectories. We previously proposed a prag
Externí odkaz:
https://doaj.org/article/9e2bc0ade09049d98f569ff3f7b8b440
Autor:
Lewis Wardale, Ryan Cardenas, Vincent J. Gnanapragasam, Colin S. Cooper, Jeremy Clark, Daniel S. Brewer
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 157-170 (2022)
Clinical management of prostate cancer is challenging because of its highly variable natural history and so there is a need for improved predictors of outcome in non-metastatic men at the time of diagnosis. In this study we calculated the model score
Externí odkaz:
https://doaj.org/article/03b0d8cad1b144c597f421031a101ad0
Autor:
Changhee Lee, Alexander Light, Evgeny S. Saveliev, Mihaela van der Schaar, Vincent J. Gnanapragasam
Publikováno v:
npj Digital Medicine, Vol 5, Iss 1, Pp 1-7 (2022)
Abstract Active Surveillance (AS) for prostate cancer is a management option that continually monitors early disease and considers intervention if progression occurs. A robust method to incorporate “live” updates of progression risk during follow
Externí odkaz:
https://doaj.org/article/6feaaabc1ede48f7bf393e53e8d66b4c
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-6 (2022)
Abstract Background Prostate cancer is an epidemic of the modern age, and despite efforts to improve awareness, it remains the case that mortality has hardly altered over the decades, driven largely by late presentation. There is a strong public perc
Externí odkaz:
https://doaj.org/article/cda84ba76ffa4154b486ad5274190f60
Autor:
Artitaya Lophatananon, Matthew H. V. Byrne, Tristan Barrett, Anne Warren, Kenneth Muir, Ibifuro Dokubo, Fanos Georgiades, Mostafa Sheba, Lisa Bibby, Vincent J. Gnanapragasam
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Introduction Pre-treatment risk and prognostic groups are the cornerstone for deciding management in non-metastatic prostate cancer. All however, were developed in the pre-MRI era. Here we compared categorisation of cancers using either only
Externí odkaz:
https://doaj.org/article/ae0344095d4c47e9b7f8801e1b6e2700
Autor:
Nikita Sushentsev, Mary A. McLean, Anne Y. Warren, Arnold J. V. Benjamin, Cara Brodie, Amy Frary, Andrew B. Gill, Julia Jones, Joshua D. Kaggie, Benjamin W. Lamb, Matthew J. Locke, Jodi L. Miller, Ian G. Mills, Andrew N. Priest, Fraser J. L. Robb, Nimish Shah, Rolf S. Schulte, Martin J. Graves, Vincent J. Gnanapragasam, Kevin M. Brindle, Tristan Barrett, Ferdia A. Gallagher
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Your paper will be accompanied by the following editor’s summary. Please let us know if there are any inaccuracies: ‘Hyperpolarised ¹³C-MRI is used to image cancer metabolism. Here the authors use this technique in prostate cancer and show that
Externí odkaz:
https://doaj.org/article/e123d7318aa540b1a93cc058ead13ca5